Puma Biotechnology Reports Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Puma Biotech (PBYI) Reports In-Line Q2 EPS, Misses on Revenue; Offers FY24 Revenue Guidance
August 1, 2024 4:44 PM EDTPuma Biotech (NASDAQ: PBYI) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $44.4 million versus the consensus estimate of $47.3 million.
GUIDANCE:
Puma Biotech sees FY2024 revenue of $183-190 million, versus the consensus... More
